Rapid7, Inc. provides cybersecurity software and services under the Rapid7, Nexpose, and Metasploit brand names. The company offers Rapid7 Insight Agent, a software-based agent that is used on assets across on-premises and cloud environments to centralize and monitor data on company's platform; Rapid7 Insight Network Sensor that analyzes raw end-to-end network traffic to increase visibility into user activity, pinpoint real threats, and investigations; Rapid7 Cloud Event Data Harvesting that offers visibility into changes made to cloud resources; and third-party integrations and ecosystem, as well as orchestration and automation solutions. It also offers various platforms, including Rapid7 managed threat complete consisting of managed detection response that delivers end-to-end threat detection and response; Rapid7 threat complete consisting of InsightIDR, a security information and event management, and extended detection and response solution; Incident Response Services to prepare and respond to potential breaches; Exposure Command, an exposure management to provide attack surface visibility; and Exposure Command Advanced to provide strong security for workloads leveraging real-time visibility, identity analysis, and automated remediation. In addition, the company provides Surface Command, a Cyber Asset Attack Service Management solution to detect and prioritize security issues from endpoint to cloud; Vector Command, a continuous red-teaming service that validates the external attack surface exposures and tests defenses; InsightCloudSec, a cloud risk and compliance management solution; InsightAppSec, a dynamic application security testing tool; and InsightVM, a vulnerability management solution that provides visibility across on-premise and remote endpoints for security. Further, it offers offloads day-to-day, advisory, and professional services. The company was incorporated in 2000 and is headquartered in Boston, Massachusetts.

Rapid7 Inc.

Royalty Pharma ( ($RPRX) ) has issued an update. On December 19, 2025, Cytokinetics announced U.S. FDA approval of MYQORZO (aficamten), a cardiac m...

Royalty Pharma Gains From FDA Approval of MYQORZO

In a report released yesterday, Gray Powell from BTIG maintained a Hold rating on Rapid7. The company’s shares closed yesterday at $15.70. Accordin...

BTIG Remains a Hold on Rapid7 (RPD)

In a report released today, Joseph Gallo from Jefferies maintained a Hold rating on Rapid7, with a price target of $18.00. Gallo covers the Technol...

Jefferies Remains a Hold on Rapid7 (RPD)

TD Cowen analyst Michael Nedelcovych maintained a Buy rating on Royalty Pharma today and set a price target of $45.00. According to TipRanks, Nedel...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	RPD	$15.33	+0.33%	352.95K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	RPD	$15.33	+0.3%	352.95K
3
4
5
6

RPD

RPD

Get Rapid7 Inc. Data in Excel

Get Rapid7 Inc. Data in Excel